Cardiac disease in pregnancy and hypertrophic cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
{{Cardiac disease in pregnancy }}
{{Cardiac disease in pregnancy }}


Line 5: Line 6:
==Overview==
==Overview==
Patients with pre-existing [[Cardiomyopathy|cardiomyopathies]] such as [[dilated cardiomyopathy]] and [[HOCM|hypertrophic cardiomyopathy]], often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during [[pregnancy]], [[labor]], and [[delivery]].  In addition to these patients, there is a subset of patients who will develop [[Peripartum cardiomyopathy|peripartum cardiomyopathy]].
Patients with pre-existing [[Cardiomyopathy|cardiomyopathies]] such as [[dilated cardiomyopathy]] and [[HOCM|hypertrophic cardiomyopathy]], often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during [[pregnancy]], [[labor]], and [[delivery]].  In addition to these patients, there is a subset of patients who will develop [[Peripartum cardiomyopathy|peripartum cardiomyopathy]].
==Pathophysiology==
==Pathophysiology==
[[Hypertrophic cardiomyopathy]] ([[HCM]]) is an autosomal dominant disease due to mutations of the cardiac sarcomere proteins, which result in asymmetric hypertrophy of the left ventricle, a nondilated left ventricular cavity, and preserved [[systolic function]] with impaired [[diastolic function]].<ref name="pmid12446072">{{cite journal| author=Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P et al.| title=Risk associated with pregnancy in hypertrophic cardiomyopathy. | journal=J Am Coll Cardiol | year= 2002 | volume= 40 | issue= 10 | pages= 1864-9 | pmid=12446072 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12446072  }} </ref>   
[[Hypertrophic cardiomyopathy]] ([[HCM]]) is an autosomal dominant disease due to mutations of the cardiac sarcomere proteins, which result in asymmetric hypertrophy of the left ventricle, a nondilated left ventricular cavity, and preserved [[systolic function]] with impaired [[diastolic function]].<ref name="pmid12446072">{{cite journal| author=Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P et al.| title=Risk associated with pregnancy in hypertrophic cardiomyopathy. | journal=J Am Coll Cardiol | year= 2002 | volume= 40 | issue= 10 | pages= 1864-9 | pmid=12446072 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12446072  }} </ref>   
Line 11: Line 11:
[[Left ventricular outflow tract obstruction]] ([[LVOT]]) is present at rest in approximately 20% of patients.<ref name="pmid16735335">{{cite journal| author=Spirito P, Autore C| title=Management of hypertrophic cardiomyopathy. | journal=BMJ | year= 2006 | volume= 332 | issue= 7552 | pages= 1251-5 | pmid=16735335 | doi=10.1136/bmj.332.7552.1251 | pmc=PMC1471918 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735335  }} </ref>
[[Left ventricular outflow tract obstruction]] ([[LVOT]]) is present at rest in approximately 20% of patients.<ref name="pmid16735335">{{cite journal| author=Spirito P, Autore C| title=Management of hypertrophic cardiomyopathy. | journal=BMJ | year= 2006 | volume= 332 | issue= 7552 | pages= 1251-5 | pmid=16735335 | doi=10.1136/bmj.332.7552.1251 | pmc=PMC1471918 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735335  }} </ref>


==Complications==
==Natural History, Complications and Prognosis==
Although most women with [[HCM]] with minimal or mild symptoms tolerate pregnancy well, the risks associated with pregnancy include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
Although most women with [[HCM]] with minimal or mild symptoms tolerate pregnancy well, the risks associated with pregnancy include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
*[[Sudden death]], particularly in patients with severe outflow obstruction or other risk factors for [[sudden cardiac death]].
*[[Sudden death]], particularly in patients with severe outflow obstruction or other risk factors for [[sudden cardiac death]].
Line 17: Line 17:


==Treatment==
==Treatment==
===Medical Therapy===
Management considerations during pregnancy, labor, and delivery include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
Management considerations during pregnancy, labor, and delivery include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
*[[Beta-blockers]] and [[calcium channel blockers]] are safe in this population.
*[[Beta-blockers]] and [[calcium channel blockers]] are safe in this population.

Revision as of 18:15, 12 April 2013

Cardiac disease in pregnancy Microchapters

Home

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

Exercise Testing

Radiation Exposure

Chest X Ray

Echocardiography

MRI

CT

Catheterization:

Pulmonary artery catheterization
Cardiac catheterization
Cardiac Ablation

Treatment

Cardiovascular Drugs in Pregnancy

Labor and delivery

Resuscitation in Late Pregnancy

Contraindications to pregnancy

Special Scenarios:

I. Pre-existing Cardiac Disease:
Congenital Heart Disease
Repaired Congenital Heart Disease
Pulmonary Hypertension
Rheumatic Heart Disease
Connective Tissue Disorders
II. Valvular Heart Disease:
Mitral Stenosis
Mitral Regurgitation
Aortic Insufficiency
Aortic Stenosis
Mechanical Prosthetic Valves
Tissue Prosthetic Valves
III. Cardiomyopathy:
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
Peripartum Cardiomyopathy
IV. Cardiac diseases that may develop During Pregnancy:
Arrhythmias
Acute Myocardial Infarction
Hypertension

Cardiac disease in pregnancy and hypertrophic cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac disease in pregnancy and hypertrophic cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac disease in pregnancy and hypertrophic cardiomyopathy

CDC on Cardiac disease in pregnancy and hypertrophic cardiomyopathy

Cardiac disease in pregnancy and hypertrophic cardiomyopathy in the news

Blogs on Cardiac disease in pregnancy and hypertrophic cardiomyopathy

Directions to Hospitals Treating Cardiac disease in pregnancy

Risk calculators and risk factors for Cardiac disease in pregnancy and hypertrophic cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Anjan K. Chakrabarti, M.D. [2]

Overview

Patients with pre-existing cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during pregnancy, labor, and delivery. In addition to these patients, there is a subset of patients who will develop peripartum cardiomyopathy.

Pathophysiology

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease due to mutations of the cardiac sarcomere proteins, which result in asymmetric hypertrophy of the left ventricle, a nondilated left ventricular cavity, and preserved systolic function with impaired diastolic function.[1]

Left ventricular outflow tract obstruction (LVOT) is present at rest in approximately 20% of patients.[2]

Natural History, Complications and Prognosis

Although most women with HCM with minimal or mild symptoms tolerate pregnancy well, the risks associated with pregnancy include:[3]

  • Sudden death, particularly in patients with severe outflow obstruction or other risk factors for sudden cardiac death.
  • Hemodynamic deterioration, particularly in those with moderate or severe symptoms before pregnancy.

Treatment

Medical Therapy

Management considerations during pregnancy, labor, and delivery include:[3]

Related Chapter

References

  1. Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P; et al. (2002). "Risk associated with pregnancy in hypertrophic cardiomyopathy". J Am Coll Cardiol. 40 (10): 1864–9. PMID 12446072.
  2. Spirito P, Autore C (2006). "Management of hypertrophic cardiomyopathy". BMJ. 332 (7552): 1251–5. doi:10.1136/bmj.332.7552.1251. PMC 1471918. PMID 16735335.
  3. 3.0 3.1 Stergiopoulos K, Shiang E, Bench T (2011). "Pregnancy in patients with pre-existing cardiomyopathies". J Am Coll Cardiol. 58 (4): 337–50. doi:10.1016/j.jacc.2011.04.014. PMID 21757110.

Template:WH Template:WS